Engineered immune cells take on tough T-Cell cancers in new trial

NCT ID NCT07070323

First seen Nov 19, 2025 · Last updated May 01, 2026 · Updated 17 times

Summary

This study tests a new treatment called CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells, modified to target and kill cancer cells. The trial will first find the safest dose and then check how well it works in shrinking tumors. About 54 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102206, China

  • Shanghai Liquan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 201418, China

  • The General Hospital of Western Theater Command PLA

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610083, China

  • Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

    RECRUITING

    Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.